Ali Ates

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Ucb Pharma, S.a., Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2012-2026.

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 6(Granted Patents)

Location History:

Marbais, BE (2012 - 2013)
Brussels, BE (2015 - 2019)

Company Filing History:

Years Active: 2012-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12649754 - Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone (2026-06-09),

2. 12643877 - Substituted tetrahydroisoquinoiline derivative as a D1 positive allosteric modulator (2026-06-02),

3. 10370355 - Tetrahydroisoquinoline derivatives (2019-08-06),

4. 10105359 - Tetrahydroisoquinoline derivatives (2018-10-23),

5. 9975873 - Isoindoline derivatives (2018-05-22),

6. 9067930 - 2-oxo-piperidinyl derivatives (2015-06-30),

7. 8586623 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-11-19),

8. 8518943 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2013-08-27),

9. 8183241 - 2-oxo-1-pyrrolidine derivatives (2012-05-22),

10. 8178533 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses (2012-05-15),

Title: The Innovative Contributions of Ali Ates

Introduction

Ali Ates is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly through his work on tetrahydroisoquinoline derivatives. With a total of 10 patents to his name, Ates has established himself as a key figure in innovation.

Latest Patents

Among his latest patents, Ates has developed tetrahydroisoquinoline derivatives that serve as Positive Allosteric Modulators of D1 receptors. These compounds are beneficial as pharmaceutical agents for the treatment of diseases where D1 receptors play a crucial role. His work in this area demonstrates a commitment to advancing medical science and improving therapeutic options.

Career Highlights

Throughout his career, Ates has worked with notable companies such as UCB Pharma and UCB Biopharma Sprl. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Ates has collaborated with esteemed colleagues, including Yannick Quesnel and Philippe Michel. These partnerships have further enhanced his innovative capabilities and have led to the development of impactful inventions.

Conclusion

Ali Ates is a distinguished inventor whose work in pharmaceuticals has the potential to transform treatment options for various diseases. His dedication to innovation and collaboration underscores the importance of research in advancing healthcare solutions.